Shilpa Medicare Limited

Valuation multiple of PE 54.08 against ROE of 9.8% signals expensive valuation relative to capital productivity; recent 99.95% 1-year return may reflect sentiment rather than fundamentals—verify sustainability

Standalone operating margin deteriorated sharply to 18.71% in Dec 2025 from the typical 29–30% range; verify whether this reflects a structural segment issue, temporary mix shift, or operational challenge

ROE of 9.8% is weak relative to consolidated operating margins of 28.25%, suggesting either capital intensity in subsidiaries, lower-margin consolidated mix, or asset-allocation inefficiency

Pharmaceutical sector exposure to government price regulation, generic competition, and biosimilar erosion; verify company's exposure to regulated segments and patent protection on key products

Consolidated revenue expanded ~26% from ₹369.97 Cr (Sep 2025) to ₹465.78 Cr (Jun 2026); verify if trajectory continues and what drives segment-level expansion

EPS recovered from Dec 2025 lows (0.84 standalone, 2.36 consolidated) to Jun 2026 levels (3.32 standalone, 5.16 consolidated); verify whether recovery reflects operational improvement or quarter-specific factors

Public float of 40.44% and 52-week price appreciation from ₹267 to ₹822 may attract institutional inflows or index inclusion; verify if self-reinforcing or dependent on fundamental catalysts

Consolidated operations at 2.5x standalone scale with multiple revenue streams; verify growth rates and profitability by segment